U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H18N4O5
Molecular Weight 334.3272
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MITOMYCIN

SMILES

[H][C@]12CN3C4=C([C@@H](COC(N)=O)[C@@]3(OC)[C@@]1([H])N2)C(=O)C(N)=C(C)C4=O

InChI

InChIKey=NWIBSHFKIJFRCO-WUDYKRTCSA-N
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1

HIDE SMILES / InChI

Description

The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour activity. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery. The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue. Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'. Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation. Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
MITOSOL
Palliative
MITOMYCIN
Palliative
MITOMYCIN

AUC

ValueDoseCo-administeredAnalytePopulation
773 μg × h/L
10 mg/m² single, intravenous
MITOMYCIN plasma
Homo sapiens
630 μg × h/L
10 mg/m² single, intravenous
MITOMYCIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
54 min
10 mg/m² single, intravenous
MITOMYCIN plasma
Homo sapiens
50 min
10 mg/m² single, intravenous
MITOMYCIN plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
76%
MITOMYCIN plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
Sponges provided within the Mitosol ® Kit should be fully saturated with the entire reconstituted contents. A treatment area approximating 10 mm x 6 mm +/- 2 mm should be treated with the Mitosol®.
Route of Administration: Topical
In Vitro Use Guide
The molecular mechanism of differentiation interruption by mitomycin C in the Non-small-cell lung cancer (NSCLC) line A549 was investigated. High dosage of mitomycin C (300 µM) could significantly inhibit cell proliferation (P < 0.05) by 48.39 ± 3.32% (P < 0.05), under which cell shrinkage and disruption were observed